Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mattersburg – page 3

55 clinical trials in Mattersburg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mattersburg at a glance
55
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

55 trials in Mattersburg

Open in trial search

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Contraception

Not recruiting

Study on the Effectiveness and Safety of Levonorgestrel Vaginal Delivery System vs. Desogestrel Tablets for Preventing Pregnancy in Women

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Desogestrel
  • Sponsor:Chemo Research S.L.

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen - Cilag International

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Preventing Heart Disease in Diabetes Patients Using Eprosartan Mesilate and Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Medical University Of Vienna

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mattersburg

What the registry says about research in the country

01 Cardiovascular Diseases

In Mattersburg, clinical trial activity in cardiovascular diseases is focused on reducing the risk of serious heart complications and improving long-term outcomes for people with atherosclerotic cardiovascular disease.

  • Studies in atherosclerotic cardiovascular disease and broader cardiovascular disease
  • Research on preventing major heart events and related complications
  • Work aimed at improving treatment effectiveness for high-risk patients

These trials are helping assess whether new therapies can better protect patients from heart attacks, cardiovascular death, and other major events.

02 Nutritional and Metabolic Diseases

Clinical research in nutritional and metabolic diseases in this Austrian city is closely linked to obesity, overweight, and related metabolic risk factors that can affect heart and kidney health.

  • Trials involving obesity and overweight
  • Studies connecting weight-related conditions with cardiovascular disease
  • Research evaluating new approaches to improve metabolic health

The main goal is to understand whether emerging treatments can lower long-term disease burden and support better prevention.

03 Cardiovascular Risk Reduction

Several trials are examining whether investigational therapies can reduce the chance of first or repeat major cardiovascular events in participants with elevated risk factors.

  • Atherosclerotic Cardiovascular Disease and event prevention
  • Elevated Lp(a) as a key risk factor under study
  • Testing new options to reduce heart-related morbidity and mortality

This research focuses on whether better risk control can help prevent heart attacks, urgent procedures, and other serious outcomes.

04 Kidney and Cardiometabolic Health

Some studies also look beyond the heart, examining whether treatments can help preserve kidney function in people with overlapping cardiometabolic conditions.

  • Chronic Kidney Disease in combination with heart risk
  • People living with obesity and related complications
  • Trials exploring whether therapy can support both heart and kidney outcomes

These projects aim to find approaches that address multiple health concerns at once, which is especially important for patients with complex chronic disease.

05 Lipoprotein(a) Research

A notable area of investigation is Lipoprotein(a), or Lp(a), where researchers are testing whether lowering this inherited risk marker can reduce cardiovascular events.

  • Elevated Lp(a) and first major cardiovascular events
  • Studies focused on preventing coronary heart disease and myocardial infarction
  • Evaluating new strategies for people at heightened genetic risk

This work could improve prevention for patients whose heart risk remains high despite standard care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.